Checkpoint Therapeutics’ (CKPT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a report issued on Monday,Benzinga reports. They currently have a $20.00 price target on the stock.

Checkpoint Therapeutics Price Performance

NASDAQ:CKPT opened at $3.57 on Monday. Checkpoint Therapeutics has a 1 year low of $1.38 and a 1 year high of $4.50. The business has a fifty day simple moving average of $3.55 and a two-hundred day simple moving average of $2.69. The company has a market capitalization of $174.33 million, a P/E ratio of -1.94 and a beta of 1.34.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). As a group, analysts anticipate that Checkpoint Therapeutics will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of Checkpoint Therapeutics in the third quarter worth $30,000. XTX Topco Ltd bought a new position in Checkpoint Therapeutics in the 2nd quarter worth about $34,000. Gladstone Institutional Advisory LLC grew its holdings in Checkpoint Therapeutics by 141.4% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 20,500 shares in the last quarter. Magnus Financial Group LLC grew its holdings in Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 4,000 shares in the last quarter. Finally, Choreo LLC increased its position in shares of Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after buying an additional 7,080 shares during the period. 22.00% of the stock is currently owned by hedge funds and other institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.